Table 2.
Summary of all PIE vitreous samples
| Patient ID | Causative injection | Pathogen | Gentamicin | Oxacillin | Cefazolin | Tetracyclin | Cotrimoxazole | Erythromycin | Clindamycin | Ciprofloxacin | Vancomycin | Rifampicin | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-pandemic | 1 | Ranibizumab | S. epidermidis | R | R | R | I | S | R | S | R | S | S |
| 2 | Triamcinolone | S. epidermidis | S | S | S | S | S | S | S | R | S | S | |
| 3 | Bevacizumab | S. epidermidis | S | S | S | I | I | R | R | R | S | S | |
| 4 | Ranibizumab | S. epidermidis | S | S | S | I | S | S | S | S | S | S | |
| 5 | Triamcinolone | S. epidermidis | S | S | S | S | R | S | S | S | S | S | |
| 6 | Aflibercept | S. epidermidis | S | S | S | I | S | R | S | S | S | S | |
| 7 | Bevacizumab | S. aureus | S | S | S | S | S | S | S | I | S | S | |
| 8 + 9 | Ranibizumab, Aflibercept | S. epidermidis * | N/A | ||||||||||
| 10–13 | Bevacizumab, Aflibercept, Bevacizumab, Triamcinolone | Unknown | |||||||||||
| Pandemic | 14 | Aflibercept | S. epidermidis | S | R | R | S | S | S | S | R | S | S |
| 15 | Aflibercept | S. epidermidis | S | N/A | R | R | S | R | N/A | I | S | S | |
| 16 | Aflibercept | S. lugdunensis | R | S | S | S | S | S | S | S | S | S | |
| 17 | Bevacizumab | S. aureus | S | S | S | S | S | S | S | S | S | S | |
| 18 | Bevacizumab | S. aureus | S | S | S | S | S | S | S | I | S | S | |
| 19 + 20 | Bevacizumab, Bevacizumab | Unknown | N/A | ||||||||||
S sensible, I inhibition, R resistant, S. Staphylococcus, N/A not available
*Detection of the bacterial strain via PCR